Due to the recent changes in the official account push mechanism, we welcome you to set Boom Health as a "star mark" on the homepage of the official account to get the latest trends and expert insights in the digital healthcare industry at the first time!
01 Overview of Global Digital Health Investment and FinancingHealx, a Drug Discovery Platform Developer, Secures $47 Million in Series C FundingOn August 1, Healx, a developer of drug discovery platforms, secured $47 million in Series C funding. The round was co-led by R42 Group and Atomico, with participation from both new and existing investors, including Balderton and Jonathan Milner. The proceeds will be used to advance the company’s drug development efforts in the fields of rare cancers, kidney diseases, and neurodevelopmental disorders, including progressing its lead program HLX-1502 into Phase 2 clinical trials for the treatment of Neurofibromatosis Type 1.Ultra-Minimally Invasive Spinal Surgery Medical Device Developer Spineology® Secures $25 Million in Series A FundingOn August 6, Spineology®, a developer of ultra-minimally invasive spinal surgery medical devices, secured $25 million in Series A financing led by SV Health Investors, with participation from 1315 Capital and its existing investor RC Capital. The funds from this round of financing will accelerate the commercial growth, clinical education initiatives, and product development of the highly differentiated OptiMesh implant portfolio.Minimally Invasive Medical Device Developer CroíValve Secures $16 Million in Series B FundingOn August 7, CroíValve, a developer of minimally invasive medical devices, secured $16 million in Series B funding. This round was led by MedTech and Irrus Syndicates, with participation from Ascentifi, Furthr, Broadview Ventures, and others. The proceeds will be used to fund the TANDEM II Early Feasibility Study, an FDA-approved prospective multicenter study designed to evaluate the safety and performance of the DUO™ System in patients with severe or more symptomatic tricuspid regurgitation.Guidehealth, an AI-powered healthcare service provider, secures $14 million in seed fundingOn August 7, Guidehealth, an AI-powered healthcare service provider, secured $14 million in seed funding led by Memorial Hermann Health System, with support from healthcare entrepreneur Sidd Pagadipati and other leaders. The funding aims to further advance Guidehealth's mission of improving health outcomes and expanding care opportunities through a value-based care model.Novel Gene Editing Technology Developer Correct Biology Secures Over 100 Million Yuan in A+ Round FinancingOn August 8, CorrectSequence Bio, a developer of novel gene-editing technologies, secured an over RMB100 million Series A+ round of financing. This round was led by Shanghai Guotou Futeng Capital, with participation from existing shareholders including Lianxin Capital, Boyu Capital, Lilly Asia Ventures, Matrix Partners, and Sequoia China, fully supporting the company’s development. The proceeds will further accelerate the clinical research and commercialization of CS-101, support the clinical translation of in vivo therapeutic pipelines, promote global expansion, and expedite the market launch of gene-editing products to benefit patients worldwide.China's ClearCorrect Brand Secures Hundreds of Millions in Series A FundingOn August 6, Chinese invisible orthodontics brand Dr. Clear aligner secured hundreds of millions in Series A funding, exclusively invested by Qiming Venture Partners. The funds will be used for the research and development and construction of fully automated production lines for invisible aligners, product development based on biomechanics, AI intelligent solution software development, and market expansion both domestically and internationally.NanoHive Medical, a Developer of 3D-Printed Spinal Interbody Implants and Instruments, Secures $7 Million in Series C FundingOn August 5, NanoHive Medical, a developer of 3D-printed spinal interbody implants and instruments, secured $7 million in Series C funding to support its continued growth. Outcome Capital served as the strategic and financial advisor in NanoHive's financing. Concurrent with the funding, the company also appointed Greg Hoffman and David Scott as board members.Ultrasound Treatment Device Developer WaveClear Completes $5 Million Series A FinancingOn August 1, ultrasound treatment device developer WaveClear completed a $5 million Series A financing round, led by Botong Medical. This investment highlights the company's potential to revolutionize the treatment of vascular diseases. The funds will support the company’s first product validation and FDA approval, accelerating its entry into the U.S. market.Early-stage Pulmonary Treatment Device Developer Nob Hill Therapeutics Secures $3 Million in Series A FundingOn August 6, Nob Hill Therapeutics, an early-stage pulmonary treatment device developer, secured $3 million in Series A funding. The round was led by new investor Tramway Venture Partners, with participation from TCA Venture Group and VIC Technology Venture Development. The proceeds will support the continued development of Nob Hill's high-dose inhalation technology and therapies, including pre-IND studies.AI-Assisted Software Provider Xinyue Intelligence Secures Million-Yuan Seed FundingOn August 6, Xinyue Intelligence, an artificial intelligence-assisted software provider, received millions of yuan in seed funding. The investors include psychology professors from Sun Yat-sen University and Guangzhou University, as well as heads of well-known investment institutions among other individual investors. The funds from this round of financing will mainly be used for product development. Xinyue Intelligence was established at the beginning of 2023 and started attempting to use AI to assist the mental health industry, officially founded in 2024. It is an artificial intelligence-assisted software designed for mental health professionals.Guan Cheng Information, a provider of whole-factory intelligent solutions, has completed its Pre-A and A rounds of financing, with a total financing amount exceeding 50 million yuan.On August 5, GTC Information, a provider of whole-factory intelligent solutions, completed its Pre-A and A rounds of financing, with a total amount exceeding 50 million yuan. The investment was jointly made by SND Finance, Mr. Zhu Guodong, and Lead Future. The funds raised will be mainly used for the continuous innovation and iteration of products, enrichment of product lines, and market expansion, further strengthening GTC Information's leading position in the digital field of the medical device industry.02 Digital Health Industry DynamicsGenome Drug Developer Sangamo Therapeutics Reaches Agreement with Genentech on Neurodegenerative DiseasesOn August 7, Sangamo Therapeutics, a leader in genomic medicine, signed a licensing agreement with Genentech, a Roche company, to develop intravenous genomic therapies for specific neurodegenerative diseases. Sangamo will be responsible for technology transfer and preclinical activities, while Genentech will handle clinical development, regulatory processes, and global commercialization.CR Pharmaceutical and Tasly Biopharmaceuticals Industry Group Reach Strategic CooperationOn August 4, China Resources Pharmaceutical Group signed a strategic cooperation agreement with Tasly Group. Both parties will collaborate in the innovation and development of traditional Chinese medicine, the Digital Herbal Medicine Large Model, and the development of pill technology and equipment. This collaboration is an important measure for all parties to complement each other's strengths, transform traditional industries with new quality productivity, develop strategic emerging industries, and lay out future industries. It holds long-term strategic significance for China Resources to play a leading and integrating role as a central enterprise in the construction of the traditional Chinese medicine industry chain.03 Overview of Global Digital Health M&AMedical Device R&D Manufacturer Zimmer Biomet Announces Acquisition of OrthoGrid SystemsOn August 7, medical technology leader Zimmer Biomet announced the acquisition of OrthoGrid Systems, a company specializing in AI-driven guidance systems for total hip replacement surgeries. The transaction includes OrthoGrid's Hip AI® platform, two additional FDA-approved orthopedic applications, and over 40 patents. OrthoGrid's AI system addresses the growing demand for fluoroscopy-based surgical guidance, enhancing Zimmer Biomet's hip product portfolio with the aim of improving intraoperative efficiency and patients' quality of life.ArteryNet/Arterial Orange Industry Think Tank/China Renaissance/China Grand Health/Rock Health/Mobile Health News/Fierce Health, etc.
Compiled by: Liu Shuxia
